Inventor · disambiguated record
Rainer Boxhammer
Also filed as: BOXHAMMER RAINER
9 granted patents·11 pending applications·45 citations·filing 2009–2024
85Inventor score
Top patents by PatentIndex Score
20 records- 0193US12194095B2Combinations and uses thereofINCYTE CORP·Filed 2021·Granted Jan 14, 2025·2 cites·28 claims
- 0289US8877899B2Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHLROJKJAER LISA·Filed 2011·Granted Nov 4, 2014·25 cites·19 claims
- 0387US9289490B2Combinations and uses thereofMORPHOSYS AG·Filed 2014·Granted Mar 22, 2016·10 cites·20 claims
- 0485US11224654B2Combinations and uses thereofMORPHOSYS AG·Filed 2016·Granted Jan 18, 2022·2 cites·18 claims
- 0581US10617691B2Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereofMORPHOSYS AG·Filed 2016·Granted Apr 14, 2020·3 cites·16 claims
- 0681US2025195646A1Combinations and uses thereofINCYTE CORP·Filed 2024·Application pending·0 cites
- 0778US9765152B2Method for the treatment of multiple myeloma or non-Hodgkins lymphoma with anti-CD38 antibody and bortezomib or carfilzomibMORPHOSYS AG·Filed 2016·Granted Sep 19, 2017·2 cites·14 claims
- 0874US10308722B2Method for the treament of multiple myeloma or non-hodgkins lymphoma with anti-CD38 antibody in combination with thalidomine, lenalidomids, or pomalidomideMORPHOSYS AG·Filed 2017·Granted Jun 4, 2019·1 cites·20 claims
- 0974US2024009196A1Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereofMORPHOSYS AG·Filed 2023·Application pending·0 cites
- 1071US2022283166A1Methods for predicting therapeutic benefit of anti-cd19 therapy in patientsMORPHOSYS AG·Filed 2022·Application pending·0 cites
- 1162US2020206228A1Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereofMORPHOSYS AG·Filed 2020·Application pending·0 cites
- 1257US2024228654A9Anti-cd38 antibodies for use in the treatment of antibody-mediated transplant rejectionMORPHOSYS AG·Filed 2022·Application pending·0 cites
- 1356US2024109977A1Anti-cd38 antibodies and their usesMORPHOSYS AG·Filed 2022·Application pending·0 cites
- 1456US2019195879A1Methods for predicting therapeutic benefit of anti-cd19 therapy in patientsMORPHOSYS AG·Filed 2017·Application pending·0 cites
- 1554US2010119506A1Effectors of PAR-2 Activation and Their Use in the Modulation of InflammationBOEHRINGER INGELHEIM INT·Filed 2009·Application pending·0 cites
- 1652US2021130461A1Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cellsMORPHOSYS AG·Filed 2020·Application pending·0 cites
- 1751US12491244B2Pharmaceutical combinations for treating tumor comprising anti-CD19 antibody and natural killer cellGC CELL CORP·Filed 2019·Granted Dec 9, 2025·0 cites·23 claims
- 1848US2022144965A1Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune diseaseMORPHOSYS AG·Filed 2020·Application pending·0 cites
- 1943US12358983B2Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereofINCYTE CORP·Filed 2017·Granted Jul 15, 2025·0 cites·20 claims
- 2033US2011311553A1Effectors of PAR-2 Activation and Their Use in the Modulation of InflammationLITZENBURGER TOBIAS·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Rainer Boxhammer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →